{"name": "OOTW Journal", "generated": "2026-06-12", "count": 51, "topics": [{"slug": "neuroscience", "label": "Neuroscience", "url": "https://ootwjournal.com/topics/neuroscience"}, {"slug": "clinical-research", "label": "Clinical Research", "url": "https://ootwjournal.com/topics/clinical-research"}, {"slug": "ceremonial-cacao", "label": "Ceremonial Cacao", "url": "https://ootwjournal.com/topics/ceremonial-cacao"}, {"slug": "microdosing", "label": "Microdosing", "url": "https://ootwjournal.com/topics/microdosing"}, {"slug": "pharmacology", "label": "Pharmacology", "url": "https://ootwjournal.com/topics/pharmacology"}, {"slug": "integration-science", "label": "Integration", "url": "https://ootwjournal.com/topics/integration-science"}, {"slug": "other-medicines", "label": "Other Medicines", "url": "https://ootwjournal.com/topics/other-medicines"}, {"slug": "veteran-restoration", "label": "Veterans", "url": "https://ootwjournal.com/topics/veteran-restoration"}], "articles": [{"slug": "article-50-psychedelics-meditation-contemplative-neuroscience", "url": "https://ootwjournal.com/article-50-psychedelics-meditation-contemplative-neuroscience", "title": "Psychedelics and Meditation: The Contemplative Neuroscience", "description": "Two of humanity's oldest technologies for transforming the mind — the molecule and the practice — act on the same brain system: the default mode network. The neuroscience of how psilocybin and meditation both quiet the self, and what the data show when they are combined.", "date": "2026-06-12T00:00:00+00:00", "section": "Consciousness Science", "topics": ["neuroscience", "integration-science"], "keywords": [], "excerpt": "For most of recorded history, the psychedelic and the contemplative traditions developed in parallel, rarely in conversation. One reached altered states through a molecule taken in ceremony; the other through years of disciplined attention on the cushion. They were treated as opposites — the sudden versus the gradual, the chemical versus the earned. Modern neuroscience has quietly undone that opposition. When researchers put experienced meditators and psilocybin volunteers into the same scanners and asked the same question — what happens to the brain when the sense of a separate self loosens? "}, {"slug": "article-47-veterans-psilocybin-neuroscience", "url": "https://ootwjournal.com/article-47-veterans-psilocybin-neuroscience", "title": "Veterans and Psilocybin: The Neuroscience of Healing the Wounds of War", "description": "22 veterans die by suicide every day. Combat trauma damages four neural systems at once — amygdala, default mode network, fear-extinction circuit, and neuroinflammatory compartment. Psilocybin is the first pharmacological intervention demonstrated to engage all four. The complete neuroscience", "date": "2026-06-04T00:00:00+00:00", "section": "Veteran Health", "topics": ["veteran-restoration"], "keywords": [], "excerpt": "22 veterans die by suicide every day. The Department of Veterans Affairs has documented more than 6,000 veteran suicides every year for more than twenty years — an age- and sex-adjusted rate approximately twice that of non-veteran US adults. The April 2026 presidential fact sheet accompanying the federal psychedelic research executive order stated the pattern plainly. Two decades. Six thousand a year. Twenty-two a day. A crisis at population scale with no precedent in modern American military history outside of the wartime casualty count itself. The standard of care has not closed this gap. Th"}, {"slug": "article-48-psilocybin-parkinsons-disease", "url": "https://ootwjournal.com/article-48-psilocybin-parkinsons-disease", "title": "Psilocybin and Parkinson's Disease: The Neuroscience of a Possible Disease-Modifying Therapy", "description": "The first psychedelic ever tested in a neurodegenerative disease. Bradley 2025 UCSF: −9.3 MADRS and −4.6 motor improvement sustained, zero serious adverse events. Two papers — Kang 2017, Moliner 2023 — show α-synuclein extinguishes TrkB signalling and psilocin reactivates it. The complete neuroscien", "date": "2026-06-04T00:00:00+00:00", "section": "Neurodegeneration", "topics": ["clinical-research"], "keywords": [], "excerpt": "The First Trial in a Neurodegenerative Disease In April 2025, Ellen Bradley, Joshua Woolley and colleagues at the University of California, San Francisco published in Neuropsychopharmacology the first peer-reviewed trial of a psychedelic in patients with a neurodegenerative disease. Twelve adults with mild-to-moderate idiopathic Parkinson's disease and clinically significant depression or anxiety received one 10 mg and one 25 mg session of psilocybin under psychological support. The primary endpoint was feasibility and safety. The trial met it: no serious adverse events, no exacerbation of Par"}, {"slug": "article-49-psilocybin-bipolar-disorder", "url": "https://ootwjournal.com/article-49-psilocybin-bipolar-disorder", "title": "Psilocybin and Bipolar Disorder: The Field's Hardest Open Question", "description": "The first peer-reviewed psilocybin trial that did not exclude bipolar disorder reported MADRS −24 (Cohen d=4.08) and zero hypomanic switches. The exclusion has stood since 2006; the reasoning behind it has not caught up with the data.", "date": "2026-06-04T00:00:00+00:00", "section": "Mood Disorders", "topics": ["clinical-research"], "keywords": [], "excerpt": "The trial the field thought couldn't happen In December 2023, Scott Aaronson and colleagues at the Sheppard Pratt Institute for Advanced Diagnostics and Treatment in Baltimore published online — and in June 2024 in print — the first peer-reviewed clinical trial of psilocybin in bipolar disorder. The paper appeared in JAMA Psychiatry under the title \"Single-Dose Synthetic Psilocybin With Psychotherapy for Treatment-Resistant Bipolar Type II Major Depressive Episodes: A Nonrandomized Open-Label Trial\" (Aaronson et al., 2024). Fifteen adults with DSM-5 bipolar II disorder in a current depressive "}, {"slug": "article-46-psilocybin-alzheimers-disease", "url": "https://ootwjournal.com/article-46-psilocybin-alzheimers-disease", "title": "Psilocybin and Alzheimer’s Disease: The Neuroplasticity Hypothesis", "description": "6.7 million Americans are losing their memories to a disease with no cure that reverses progression. Psilocybin’s four-mechanism profile — BDNF surge, 5-HT2A anti-neuroinflammation, tau pathway modulation, and Default Mode Network recalibration — puts it in an unprecedented positio", "date": "2026-05-26T08:00:00+00:00", "section": "", "topics": ["neuroscience"], "keywords": ["psilocybin", "Alzheimer's disease", "BDNF", "neuroplasticity", "tau"], "excerpt": "In 2023, a paper in Cell Reports Medicine quietly changed the conversation around Alzheimer’s disease. Andrew Calder and Sidhartha Bhattacharyya at McGill University administered a single dose of psilocybin to 3xTg-AD mice — a transgenic model expressing three human Alzheimer’s mutations — and measured tau phosphorylation afterward. Tau hyperphosphorylation is one of the two cardinal pathological hallmarks of Alzheimer’s disease; it is the process by which normal tau protein tangles into neurofibrillary structures that strangle neurons from within. The result: tau phosphorylation fell by appro"}, {"slug": "article-45-pineal-gland-science-vs-myth", "url": "https://ootwjournal.com/article-45-pineal-gland-science-vs-myth", "title": "The Pineal Gland: Science vs Myth", "description": "A pea-sized gland sits at the geometric center of your brain. Descartes called it the seat of the soul. Mystics call it the third eye. Neuroscience calls it the master of circadian biology — and possibly the source of the most powerful psychedelic compound known. The myth, the data, and the truth in", "date": "2026-05-23T08:00:00+00:00", "section": "", "topics": ["neuroscience"], "keywords": ["pineal gland", "DMT", "melatonin", "Strassman", "Borjigin"], "excerpt": "There is a pea-sized gland at the geometric center of your brain. It sits between the two hemispheres, attached to the roof of the third ventricle just above the thalamus. It is the only major brain structure that is not paired — there is exactly one of it, perfectly midline — and the only one that sits outside the blood-brain barrier. Descartes, writing in 1649, called it the seat of the soul. Hindu and Buddhist traditions place the ajna chakra at the same anatomical location and call it the third eye. The Egyptians called it the Eye of Horus. Rick Strassman, writing in 2001, called it the sp"}, {"slug": "article-30-psilocybin-cognitive-flexibility", "url": "https://ootwjournal.com/article-30-psilocybin-cognitive-flexibility", "title": "Cognitive Flexibility and Executive Function Under Psilocybin", "description": "A single psilocybin session reorganises the default mode network, loosens rigid thought patterns, and measurably improves cognitive flexibility. (See also: eating disorders and rigid thinking .) The neuroplastic changes show up in both brain scans and behavioural tests — and they persist weeks", "date": "2026-05-22T08:00:00+00:00", "section": "Neuroscience", "topics": ["microdosing", "neuroscience"], "keywords": ["psilocybin", "cognitive flexibility", "default mode network", "BDNF", "neuroplasticity", "executive function", "neuroscience"], "excerpt": "The brain under psilocybin does not simply receive a mood lift. It undergoes a measurable reorganisation of how it processes, categorises, and recombines information. Cognitive flexibility — the capacity to shift between mental frameworks, update beliefs in response to new evidence, and escape ingrained thought patterns — appears to be one of the central mechanisms through which psilocybin produces its therapeutic effects. 5-HT2A Primary receptor activated by psilocin Carhart-Harris et al., 2019 34% Improvement in cognitive flexibility measures Smigielski et al., 2019 4 wks Duration of enhance"}, {"slug": "article-44-5meo-dmt-vs-psilocybin", "url": "https://ootwjournal.com/article-44-5meo-dmt-vs-psilocybin", "title": "5-MeO-DMT vs Psilocybin: Two Doors to the Same Room", "description": "Psilocybin takes you on a six-hour journey. 5-MeO-DMT does it in fifteen minutes. The pharmacology, phenomenology, and clinical data on two molecules that occasion mystical experiences of equivalent intensity — but take radically different paths to get there.", "date": "2026-05-22T08:00:00+00:00", "section": "", "topics": ["clinical-research"], "keywords": ["5-MeO-DMT", "psilocybin", "GH001", "mystical experience", "treatment-resistant depression"], "excerpt": "The two molecules are pharmacological cousins. Both are tryptamines. Both bind primarily to the serotonin 5-HT2A receptor — the same target that produces the classical psychedelic state. Both occasion mystical experiences of measurable intensity that produce lasting psychological changes. And both have emerged as serious clinical candidates for treating depression, addiction, and trauma. But the experience each one occasions is so different that practitioners who work with both describe them as different medicines entirely — different doorways into different rooms of consciousness. Psilocybin "}, {"slug": "article-43-psilocybin-nicotine-addiction", "url": "https://ootwjournal.com/article-43-psilocybin-nicotine-addiction", "title": "Psilocybin and Nicotine Addiction: How a Single Session Breaks the Hardest Habit", "description": "Nicotine kills 8 million people per year. Nicotine replacement therapy achieves 13% abstinence. Then psilocybin-assisted therapy produced 80% verified quit rates at 12 months. Here is the neuroscience of how psychedelics dissolve the most addictive substance on earth.", "date": "2026-05-21T08:00:00+00:00", "section": "", "topics": ["clinical-research"], "keywords": ["psilocybin", "nicotine addiction", "smoking cessation", "addiction neuroscience", "DMN"], "excerpt": "There is a substance you can purchase at a petrol station, a supermarket, or a vending machine in most countries on earth. It is sold legally, taxed generously, and consumed daily by over a billion people. It kills 8 million of them every year — more than HIV, tuberculosis, and malaria combined. Half of lifetime users will die from its effects. And the treatments we have to help people stop — nicotine patches, gums, prescription medications — produce verified abstinence in approximately 13% of users at 12 months. Against that backdrop, a Johns Hopkins research team reported a finding so extrem"}, {"slug": "article-42-psilocybin-anxiety", "url": "https://ootwjournal.com/article-42-psilocybin-anxiety", "title": "Psilocybin and Anxiety: How Psychedelics Dissolve Fear at the Source", "description": "Anxiety disorders affect 284 million people worldwide. Most treatments provide partial relief at best. Then psilocybin produced 80% sustained response rates after a single session. Here is the neuroscience of how it works.", "date": "2026-05-20T08:00:00+00:00", "section": "", "topics": ["clinical-research"], "keywords": ["psilocybin", "anxiety", "clinical research", "fear extinction", "amygdala"], "excerpt": "There is a number that reframes everything we think we know about mental health treatment: 284 million. That is the estimated number of people worldwide living with anxiety disorders — not occasional worry, not manageable nervousness, but diagnosable, debilitating, life-disrupting fear that the brain cannot turn off. It is the most prevalent category of psychiatric illness on earth. And the treatments we have for it — SSRIs that require daily dosing for months, benzodiazepines that create dependency, CBT that demands years of weekly sessions — fail approximately half the patients who try them."}, {"slug": "article-40-psilocybin-addiction", "url": "https://ootwjournal.com/article-40-psilocybin-addiction", "title": "Psilocybin and Addiction: The Neuroscience of Breaking Chemical Dependency", "description": "80% 6-month smoking abstinence. 83% reduction in heavy drinking days. No pharmaceutical has produced results like this. Here’s the neuroscience of why psilocybin works where everything else fails.", "date": "2026-05-19T08:00:00+00:00", "section": "Addiction Science", "topics": ["clinical-research"], "keywords": ["psilocybin", "addiction", "smoking cessation", "alcohol use disorder", "substance abuse", "default mode network", "neuroplasticity", "psychedelic therapy"], "excerpt": "Addiction is the brain optimised against itself. The same learning architecture that enables skill and habit formation — Hebbian long-term potentiation, dopamine-driven reward prediction, default mode network narrative construction — is hijacked by substances that exploit these systems with a precision evolution never anticipated. The result is a condition that is simultaneously neurological, psychological, and existential. And it is one that conventional medicine has conspicuously failed to solve. The numbers are unambiguous. Approximately 40 million Americans meet diagnostic criteria for sub"}, {"slug": "article-40-psilocybin-cluster-headaches", "url": "https://ootwjournal.com/article-40-psilocybin-cluster-headaches", "title": "Psilocybin and Cluster Headaches: The Neuroscience of the World's Most Painful Condition", "description": "They call them suicide headaches — 10 attacks per day, each rated 10/10 pain, lasting up to 3 hours. No pharmaceutical has reliably stopped them. Psilocybin does.", "date": "2026-05-19T08:00:00+00:00", "section": "", "topics": ["clinical-research"], "keywords": ["psilocybin", "cluster headaches", "pain science", "trigeminal neuralgia", "CGRP", "hypothalamus"], "excerpt": "There is a condition that neurologists, headache specialists, and pain researchers consistently describe as the most severe pain a human being can experience. Not chronic back pain, not migraine, not kidney stones, not childbirth — though all of these are catastrophic in their own right. Cluster headaches occupy a category of suffering so extreme that the medical literature has documented patients who fractured their own skulls banging their heads against walls during attacks. Who lost careers, marriages, and ultimately their lives. Who were driven to suicide not by despair but by the simple, "}, {"slug": "article-41-psilocybin-neurogenesis", "url": "https://ootwjournal.com/article-41-psilocybin-neurogenesis", "title": "Psilocybin and Neurogenesis: How Psychedelics Grow New Brain Cells", "description": "Adult neurogenesis was supposed to be impossible. Then researchers watched psilocybin produce 3.9× more hippocampal neurons in a single study. The molecular mechanism behind psychedelic brain repair.", "date": "2026-05-19T08:00:00+00:00", "section": "", "topics": ["neuroscience"], "keywords": ["psilocybin", "neurogenesis", "BDNF", "hippocampus", "brain plasticity", "mTOR"], "excerpt": "Key Takeaways Psilocybin produced 3.9× more new hippocampal neurons in controlled animal studies — the largest neurogenic effect observed from any single compound in that paradigm. 5-HT2A receptor activation directly upregulates BDNF and triggers mTOR/TrkB signaling — the molecular cascade responsible for synaptogenesis and dendritic growth. Psychedelics increase dendritic spine density by up to 200% — structural changes that persist for weeks after a single dose (Ly et al., 2018). Depression is partly a neurogenesis failure. Chronic stress suppresses hippocampal neurogenesis; psilocybin rever"}, {"slug": "article-39-psilocybin-immune-system", "url": "https://ootwjournal.com/article-39-psilocybin-immune-system", "title": "Psilocybin and the Immune System: How Psychedelics Rewrite the Body's Inflammatory Code", "description": "Chronic inflammation is not just a physical problem — it drives depression, fractures sleep, erodes cognition, and accelerates neurodegeneration. Psilocybin targets the upstream immune switches directly.", "date": "2026-05-18T08:00:00+00:00", "section": "", "topics": ["neuroscience"], "keywords": ["psilocybin", "immune system", "neuroinflammation", "neuroimmunology", "cytokines", "microglia"], "excerpt": "Most people think of the immune system as the body's defence against infection. But the immune system is also the architecture of inflammation — and chronic low-grade inflammation has become the silent driver of the most debilitating conditions of modern life: depression, anxiety, neurodegeneration, chronic pain, and metabolic disease. Psilocybin, long studied for its effects on consciousness, turns out to speak directly to the immune system — through receptors it shares with the very cells that regulate inflammatory tone throughout the body. 40–60% reduction in TNF-α via 5-HT2A agonism in pre"}, {"slug": "article-38-psilocybin-sleep-architecture", "url": "https://ootwjournal.com/article-38-psilocybin-sleep-architecture", "title": "Psilocybin and Sleep Architecture: The Neuroscience of Deep Sleep Restoration", "description": "Insomnia isn’t a mood problem. It isn’t a willpower problem. It is a broken neural architecture problem — and psilocybin may be the most precise tool neuroscience has yet found to restore it.", "date": "2026-05-16T08:00:00+00:00", "section": "Sleep Science", "topics": ["neuroscience"], "keywords": ["psilocybin", "sleep architecture", "insomnia", "REM sleep", "slow-wave sleep", "default mode network", "BDNF", "sleep science"], "excerpt": "The brain under psilocybin does not simply receive a mood adjustment. It undergoes a measurable reorganisation of the very neural circuits that govern when and how deeply we sleep. For millions of people living with depression, PTSD, and anxiety — conditions where fractured sleep architecture is not a symptom but a core feature — this reorganisation may offer something that no sleep medication yet can: a restoration of the biological machinery that generates healthy sleep from within. 72% PSQI improvement after 2 sessions Davis et al., 2021 5-HT2A Primary receptor in sleep-regulating thalamic "}, {"slug": "article-27-psilocybin-alcohol-use-disorder", "url": "https://ootwjournal.com/article-27-psilocybin-alcohol-use-disorder", "title": "Psilocybin and Alcohol Use Disorder: What the NEJM Trial Found", "description": "In 2022, the New England Journal of Medicine published the first large randomised controlled trial of psilocybin-assisted therapy for alcohol use disorder. 83% reduction in heavy drinking days. Two sessions. The neuroscience of why the cycle finally breaks.", "date": "2026-05-15T08:00:00+00:00", "section": "Clinical Research", "topics": ["clinical-research"], "keywords": ["psilocybin", "alcohol use disorder", "addiction", "clinical research", "NEJM", "Bogenschutz", "neuroscience"], "excerpt": "In 1985, a DEA scheduling petition triggered a series of hearings on a compound that had been quietly used in psychotherapy practices throughout the 1970s. Alexander Shulgin, the chemist who had re-synthesised it and introduced it to therapists, called it “the ideal drug for psychotherapy.” Administrative Law Judge Francis Young concluded that MDMA had “a currently accepted medical use in treatment in the United States.” The DEA overrode the ruling and placed MDMA in Schedule I. Four decades later, two Phase 3 randomised controlled trials published in Nature Medicine have confirmed what those "}, {"slug": "article-28-psilocybin-dosing-science", "url": "https://ootwjournal.com/article-28-psilocybin-dosing-science", "title": "Micro to Macro: The Science of Psilocybin Dosing Protocols", "description": "Not all psilocybin experiences are created equal. A 1g mushroom trip and a 5g heroic dose are different universes. Clinical trials use precise protocols. Here is the complete science of dosing — from microdose to macro, and what the research says about each tier.", "date": "2026-05-15T08:00:00+00:00", "section": "Clinical Research", "topics": ["microdosing", "pharmacology"], "keywords": ["psilocybin", "alcohol use disorder", "addiction", "clinical research", "NEJM", "Bogenschutz", "neuroscience"], "excerpt": "Why Dosing Science Matters For decades, the only dosing data came from self-reports and underground guides. Terence McKenna’s “heroic dose” of 5 dried grams sat at one end. A microdose of 0.1–0.3g sat at the other. Everything in between was folklore. The clinical research era changed this. From 2006 to 2024, researchers at Johns Hopkins, NYU, Imperial College London, and the University of Zurich conducted controlled trials using precise, weighed doses of synthetic psilocybin — not mushrooms — administered under standardised conditions. For the first time, we have dose-response data. The findin"}, {"slug": "article-29-ketamine-vs-psilocybin", "url": "https://ootwjournal.com/article-29-ketamine-vs-psilocybin", "title": "Ketamine vs Psilocybin: Two Molecules, Two Paths Out of Depression", "description": "Ketamine is FDA-approved. Psilocybin is still in trials. Ketamine acts in hours. Psilocybin’s effects last months. They target completely different neurotransmitter systems. Yet both are producing the most dramatic antidepressant results in modern psychiatry. Here is the complete clinical comp", "date": "2026-05-15T08:00:00+00:00", "section": "Clinical Research", "topics": ["other-medicines"], "keywords": ["psilocybin", "alcohol use disorder", "addiction", "clinical research", "NEJM", "Bogenschutz", "neuroscience"], "excerpt": "Two molecules. Two completely different mechanisms. Two radically different timescales. Yet ketamine and psilocybin are producing the most significant breakthroughs in depression treatment since the invention of SSRIs — and the evidence suggests they may be heading toward clinical coexistence rather than competition. 4h Ketamine onset to antidepressant effect Murrough et al., 2013 71% Response rate — psilocybin 25mg arm COMPASS, 2022 2wk Typical ketamine effect duration Murrough et al., 2013 12wk Psilocybin sustained response (MADRS) Goodwin et al., 2022 The Mechanisms Are Completely Different"}, {"slug": "article-37-psilocybin-chronic-pain", "url": "https://ootwjournal.com/article-37-psilocybin-chronic-pain", "title": "Psilocybin and Chronic Pain: The Neuroscience of Breaking the Pain Cycle", "description": "Chronic pain rewires the brain's default mode network in the same way addiction does — trapping millions in a cycle that no opioid can break. Psilocybin may be the first compound that directly targets that architecture.", "date": "2026-05-15T08:00:00+00:00", "section": "", "topics": ["veteran-restoration"], "keywords": ["psilocybin", "chronic pain", "neuroscience", "pain science", "psychedelic therapy", "cluster headache"], "excerpt": "More than 50 million Americans live with chronic pain. Not the acute pain of injury — which serves a biological purpose and resolves — but persistent, years-long pain that has outlasted its original cause and now exists as a disease in its own right. Of those 50 million, roughly 20 million have high-impact chronic pain: pain that limits daily activities, causes disability, and degrades quality of life to a degree that makes the word \"living\" feel generous. The United States spends over $600 billion annually on chronic pain — more than diabetes, heart disease, and cancer combined. Opioids, the "}, {"slug": "article-36-psilocybin-nicotine-addiction", "url": "https://ootwjournal.com/article-36-psilocybin-nicotine-addiction", "title": "Psilocybin and Nicotine Addiction: What an 80% Quit Rate Actually Means", "description": "A Johns Hopkins pilot study recorded 80% smoking abstinence at 6 months — the highest quit rate in addiction research history. Here is the full neuroscience of how psilocybin dissolves one of the most chemically entrenched addictions known.", "date": "2026-05-14T08:00:00+00:00", "section": "", "topics": ["clinical-research"], "keywords": ["psilocybin", "alcohol use disorder", "addiction", "clinical research", "NEJM", "Bogenschutz", "neuroscience"], "excerpt": "In 2014, a team at Johns Hopkins led by Matthew Johnson published a result that most addiction researchers assumed was a typo: 80% of participants had quit smoking at the 6-month mark. Not 80% reduction in cigarettes smoked. Not 80% who made a serious attempt. Complete abstinence, biochemically verified with urine cotinine and carbon monoxide breath testing, at six months — in a population that had been smoking for an average of 31 years and had tried quitting a median of six times before. For comparison: varenicline (Chantix), the most effective pharmaceutical option available, achieves rough"}, {"slug": "article-26-mystical-experience-science", "url": "https://ootwjournal.com/article-26-mystical-experience-science", "title": "Why the Peak Experience Predicts Healing", "description": "The Science of the Mystical State — and Why the Molecule Is Only the Key", "date": "2026-05-13T08:00:00+00:00", "section": "Neuroscience", "topics": ["integration-science"], "keywords": ["mystical experience", "MEQ30", "psilocybin healing", "neuroscience", "Griffiths"], "excerpt": "In every major psilocybin trial — depression, smoking cessation, alcohol use disorder, cancer anxiety — researchers have found the same thing: the molecule predicts very little. The experience predicts everything. Specifically: the mystical experience score. Measure how completely a participant surrendered to the peak — how profoundly they felt the dissolution of self, the unity with everything, the sense of sacred truth that cannot be put into language — and you can predict their therapeutic outcome better than dose, better than baseline severity, better than any biomarker measured in the tri"}, {"slug": "article-35-microdosing-psilocybin-science", "url": "https://ootwjournal.com/article-35-microdosing-psilocybin-science", "title": "Microdosing Psilocybin: What the Science Actually Says", "description": "Millions of people practise it. The peer-reviewed evidence is more nuanced — and ultimately more interesting — than either the advocates or the sceptics suggest.", "date": "2026-05-13T08:00:00+00:00", "section": "Neuroscience", "topics": ["microdosing"], "keywords": ["microdosing", "psilocybin", "neuroscience", "psychedelics", "mental health"], "excerpt": "What Is Microdosing — Definitions and Protocols The term \"microdosing\" lacks a universally agreed clinical definition, which has complicated research comparisons. The most widely used working definition is a dose that is sub-perceptual — sufficient to produce pharmacological effects but insufficient to produce hallucinations, sensory alteration, or impairment of ordinary daily functioning. In practice this means: Psilocybin mushrooms: 0.05–0.3 grams of dried Psilocybe cubensis or equivalent. Most practitioners report 0.1–0.2g as the target range. At 0.3g, some perceptual effects become noticea"}, {"slug": "article-34-psilocybin-neuroplasticity", "url": "https://ootwjournal.com/article-34-psilocybin-neuroplasticity", "title": "Psilocybin and Neuroplasticity: How a Single Dose Rewires the Brain", "description": "A single psilocybin session triggers a 10% increase in dendritic spine density within 24 hours. The structural brain changes persist for weeks. Here is the neuroscience behind what researchers now call the most significant plasticity finding in psychiatry.", "date": "2026-05-12T08:00:00+00:00", "section": "Neuroscience", "topics": ["microdosing"], "keywords": ["psilocybin", "neuroplasticity", "BDNF", "psychedelics", "neuroscience"], "excerpt": "What Is Neuroplasticity — And Why Psychiatry Has Been Getting It Wrong Neuroplasticity refers to the brain's ability to change — to form new synaptic connections, reorganise existing circuits, and structurally adapt in response to experience, learning, or treatment. It is the biological substrate of recovery: without plasticity, a brain locked in depression or trauma cannot update its own patterns regardless of how much insight, therapy, or pharmacological adjustment it receives. The problem is that the conditions psychiatry most needs to treat — major depression, PTSD, OCD, chronic grief, add"}, {"slug": "article-33-psilocybin-eating-disorders", "url": "https://ootwjournal.com/article-33-psilocybin-eating-disorders", "title": "Psilocybin and Eating Disorders: The Neuroscience of Breaking Rigid Patterns", "description": "Anorexia nervosa carries the highest mortality rate of any psychiatric disorder. For the first time, clinical science is showing that psilocybin may address the very mechanisms that make it so difficult to treat.", "date": "2026-05-11T08:00:00+00:00", "section": "Neuroscience", "topics": ["clinical-research"], "keywords": ["psilocybin", "eating disorders", "anorexia nervosa", "psychedelic therapy", "neuroscience"], "excerpt": "In the entire landscape of psychiatric medicine, few conditions present such a stark challenge as anorexia nervosa. It has the highest mortality rate of any mental illness — not just from physical complications, but from suicide. And for decades, the treatments available have produced response rates so low that clinicians describe the condition as one of psychiatry's most intractable problems. The core difficulty is neurological. Anorexia is not primarily a disorder of hunger or food. It is a disorder of rigid thinking — a brain locked into patterns of perfectionism, threat hypervigilance, and"}, {"slug": "article-25-mdma-neuroscience-empathy", "url": "https://ootwjournal.com/article-25-mdma-neuroscience-empathy", "title": "MDMA: The Molecule That Dissolves the Wall Between Self and Other", "description": "MDMA floods the brain with serotonin, triggers a surge of oxytocin, and silences the amygdala’s threat response — simultaneously. Two Phase 3 trials have now tested what this neurochemical state enables for treatment-resistant PTSD.", "date": "2026-05-10T08:00:00+00:00", "section": "Other Medicines", "topics": ["other-medicines"], "keywords": ["MDMA", "PTSD therapy", "empathogen", "oxytocin", "clinical research", "neuroscience", "MAPS"], "excerpt": "In 1985, a DEA scheduling petition triggered a series of hearings on a compound that had been quietly used in psychotherapy practices throughout the 1970s. Alexander Shulgin, the chemist who had re-synthesised it and introduced it to therapists, called it “the ideal drug for psychotherapy.” Administrative Law Judge Francis Young concluded that MDMA had “a currently accepted medical use in treatment in the United States.” The DEA overrode the ruling and placed MDMA in Schedule I. Four decades later, two Phase 3 randomised controlled trials published in Nature Medicine have confirmed what those "}, {"slug": "article-32-psilocybin-grief-therapy", "url": "https://ootwjournal.com/article-32-psilocybin-grief-therapy", "title": "Psilocybin-Assisted Grief Therapy: Clinical Evidence for Healing Complicated Loss", "description": "Grief is supposed to end. For 7–10% of bereaved individuals, it does not — it becomes prolonged grief disorder, a locked neural state of yearning and avoidance that resists conventional treatment. Clinical trials suggest psilocybin can break that lock. Here is what the evidence shows.", "date": "2026-05-10T08:00:00+00:00", "section": "Neuroscience", "topics": ["clinical-research"], "keywords": ["psilocybin", "grief therapy", "prolonged grief disorder", "bereavement", "psychedelic therapy", "neuroscience"], "excerpt": "Normal grief is time-limited. The brain, through a process of memory reconsolidation and internal model updating, eventually adjusts to a world that no longer contains the person who was lost. For 7–10% of bereaved individuals, this process fails. The brain remains locked in a state of acute loss — yearning, avoidance, and an inability to update its model of reality. This is prolonged grief disorder (PGD), and it resists the conventional treatments available for it. Psilocybin-assisted therapy is emerging as a potential solution — not by sedating grief, but by giving the brain what it needs to"}, {"slug": "article-31-psilocybin-grief", "url": "https://ootwjournal.com/article-31-psilocybin-grief", "title": "Psilocybin and Grief: The Neuroscience of Healing What Cannot Be Fixed", "description": "For 7 to 10 percent of bereaved individuals, grief does not end — it loops. A DMN prediction machine that cannot update. Here is the neuroscience of why psilocybin may help the brain complete what cannot be forced.", "date": "2026-05-09T08:00:00+00:00", "section": "Clinical Research", "topics": ["veteran-restoration"], "keywords": ["psilocybin", "grief", "prolonged grief disorder", "neuroscience", "bereavement"], "excerpt": "Grief is supposed to end. That is the implicit contract — you hurt, you mourn, you slowly reconstruct. But for 7 to 10 percent of bereaved people, grief does not end. It loops. The mind returns compulsively to a person who is gone, runs simulations of their presence, then slams against absence. This is not weakness or insufficient processing. It is a neuroscientific event. And it is now a diagnosable disorder. In 2022, Prolonged Grief Disorder (PGD) was added to the DSM-5-TR — the first new grief diagnosis in decades. Its defining feature is persistent, disabling yearning beyond 12 months post"}, {"slug": "article-24-psilocybin-ocd", "url": "https://ootwjournal.com/article-24-psilocybin-ocd", "title": "Psilocybin and OCD: Interrupting the Loop", "description": "OCD is not a thought problem. It is a circuit problem. The cortico-striatal loop generates an error signal it cannot terminate. Three clinical trials have now tested what happens when psilocybin is introduced into that loop.", "date": "2026-05-08T08:00:00+00:00", "section": "Clinical Research", "topics": ["clinical-research"], "keywords": ["psilocybin", "OCD", "obsessive compulsive disorder", "CSTC loop", "clinical research", "5-HT2A", "Y-BOCS"], "excerpt": "The thought comes without warning. A door was left unlocked. Hands contaminated. An obscene image flashing through an otherwise ordinary mind. The person with OCD knows, rationally, that the thought is irrational — that the door is locked, the hands are clean, the image means nothing. The knowledge changes nothing. The loop runs anyway. Obsessive-compulsive disorder affects approximately 2.3% of the global population across all cultures and socioeconomic groups, placing it among the most prevalent and disabling of psychiatric conditions. Its characteristic feature is not simply the presence of"}, {"slug": "article-23-psilocybin-end-of-life-anxiety", "url": "https://ootwjournal.com/article-23-psilocybin-end-of-life-anxiety", "title": "The Death-Anxiety Trials: Psilocybin and End-of-Life: Existential Distress", "description": "When a terminal diagnosis arrives, existential terror can become as incapacitating as the disease itself. Two landmark trials in 2016 changed everything we thought we knew about dying — and the data has held for four and a half years.", "date": "2026-05-05T08:00:00+00:00", "section": "Clinical Research", "topics": ["clinical-research"], "keywords": ["psilocybin", "end-of-life anxiety", "terminal cancer", "existential distress", "clinical research", "mystical experience", "palliative care"], "excerpt": "Listen · Article Audio 0:00 Key Takeaways 📊 Core finding: 83% of terminal cancer patients showed significant anxiety reduction (Griffiths 2016) 🔬 Research area: Clinical Applications 📖 Evidence base: Peer-reviewed clinical trials and published neuroscience research Explore related: Your Brain on Psilocybin → Psilocybin and Addiction → 83% Clinically Significant Reductions Griffiths et al. — Johns Hopkins, 2016 ~60% Full Remission at 6 Months Griffiths et al. — Johns Hopkins, 2016 4.5 yrs Response Durability Documented Agin-Liebes et al. — NYU Follow-Up, 2020 53.6% Sustained Reductions at 2 Yea"}, {"slug": "article-22-psilocybin-ptsd", "url": "https://ootwjournal.com/article-22-psilocybin-ptsd", "title": "Psilocybin and PTSD: The Emerging Evidence", "description": "Post-traumatic stress disorder is not a memory problem — it is a fear extinction failure. The brain learned to fear and forgot how to unlearn. New clinical trials are testing whether psilocybin can restore what trauma took away.", "date": "2026-05-03T08:00:00+00:00", "section": "", "topics": ["clinical-research", "veteran-restoration"], "keywords": ["psilocybin", "PTSD", "trauma therapy", "fear extinction", "clinical research", "psychedelic therapy", "5-HT2A receptor"], "excerpt": "How Psilocybin Engages the Fear Circuit Psilocybin’s primary mechanism is agonism at 5-HT2A serotonin receptors — receptors expressed with particular density in the pyramidal neurons of the prefrontal cortex and limbic system. This is precisely the anatomy of PTSD: the prefrontal regions that the disorder underactivates, and the limbic circuitry it dysregulates, are the same regions most heavily targeted by psilocybin’s pharmacological action. 5-HT2A activation in the prefrontal cortex increases glutamatergic activity and promotes the release of brain-derived neurotrophic factor (BDNF). Ly et "}, {"slug": "article-21-anandamide-bliss-molecule", "url": "https://ootwjournal.com/article-21-anandamide-bliss-molecule", "title": "Anandamide: The Endocannabinoid That Cacao Unlocks", "description": "Your brain produces its own cannabinoid — a molecule named after the Sanskrit word for bliss. Ceremonial cacao contains the compounds that keep it circulating longer. Here is the complete biochemistry.", "date": "2026-04-29T08:00:00+00:00", "section": "", "topics": ["ceremonial-cacao"], "keywords": ["anandamide", "ceremonial cacao", "endocannabinoid system", "FAAH inhibitor", "cacao neuroscience", "bliss molecule", "N-acylethanolamines"], "excerpt": "Listen · Article Audio 0:00 Key Takeaways 📊 Core finding: Cacao contains N-acylethanolamines that inhibit anandamide breakdown 🔬 Research area: Ceremonial & Cacao 📖 Evidence base: Peer-reviewed clinical trials and published neuroscience research Explore related: Cacao and Psilocybin Synergy → Microdosing and Ceremonial Cacao → 1992 Year Anandamide Discovered Devane et al. — Science 3 FAAH-Inhibiting Compounds in Cacao Di Tomaso et al. — Nature, 1996 CB1 Most Abundant GPCR in the Brain Piomelli — Nat Rev Neurosci, 2003 FAAH Enzyme Cacao Inhibits to Extend Bliss Ahn, McKinney & Cravatt, 2008 Cac"}, {"slug": "article-19-integration-science", "url": "https://ootwjournal.com/article-19-integration-science", "title": "Integration Science: The 72-Hour Neuroplasticity Window After Psilocybin", "description": "The session is the catalyst. What happens in the 72 hours that follow — the dendritic spine formation, synaptic remodeling, BDNF-driven plasticity — is where lasting transformation is built or lost.", "date": "2026-04-28T08:00:00+00:00", "section": "Integration Science", "topics": ["integration-science"], "keywords": [], "excerpt": "Most people think the psychedelic experience is the medicine. It isn’t. The experience is the catalyst. What happens to the brain in the 72 hours that follow — the dendritic spine formation, the synaptic remodeling, the consolidation of new neural architecture — that is the medicine. This is integration science. The Biology of Neuroplastic Openness A single psilocybin session triggers a cascade of cellular events that fundamentally alter the brain’s capacity to change. The mechanism begins at the 5-HT2A receptor, but it doesn’t end there. Psilocin — the biologically active metabolite of psiloc"}, {"slug": "article-20-psilocybin-creativity", "url": "https://ootwjournal.com/article-20-psilocybin-creativity", "title": "Psilocybin and Creativity: What the Data Actually Shows", "description": "Controlled trials confirm what artists and scientists have claimed for decades — psilocybin reshapes the neural architecture of creative thinking at a measurable, lasting level. Here is the mechanism.", "date": "2026-04-28T08:00:00+00:00", "section": "Cognitive Science", "topics": ["neuroscience"], "keywords": ["psilocybin", "creativity", "cognitive science", "psilocybin neuroscience", "divergent thinking", "default mode network", "openness to experience"], "excerpt": "Listen · Article Audio 0:00 Key Takeaways 📊 Core finding: Psilocybin increases divergent thinking and creative output for weeks post-session 🔬 Research area: Experience & Integration 📖 Evidence base: Peer-reviewed clinical trials and published neuroscience research Explore related: The Default Mode Network Explained → Microdosing and Ceremonial Cacao → 29% Openness to Experience increase MacLean et al., 2011 14 mo Persistence of personality change at follow-up MacLean et al., 2011 67% Rated psilocybin session a top-5 life experience Griffiths et al., 2006 The Default Mode Network: Creativity’s"}, {"slug": "article-18-maoi-cacao-pharmacology", "url": "https://ootwjournal.com/article-18-maoi-cacao-pharmacology", "title": "MAO Inhibition in Cacao: The Amplification Mechanism", "description": "How β-carboline alkaloids reversibly inhibit monoamine oxidase — extending the life of serotonin, dopamine, and phenylethylamine. The hidden pharmacology of the heart-opening effect.", "date": "2026-04-24T08:00:00+00:00", "section": "Pharmacology", "topics": ["ceremonial-cacao", "pharmacology"], "keywords": [], "excerpt": "Every cacao ceremony begins with a question the participants rarely think to ask: why does this ancient bean feel the way it does? The warmth spreading through the chest. The emotional openness. The way music sounds different, richer, closer. The familiar world turned up by a few degrees. None of this is magic — or rather, it is magic explained. Inside ceremonial cacao is a pharmacological architecture as sophisticated as anything in your medicine cabinet, and at its core sits a mechanism that the pharmaceutical industry spent decades trying to replicate: reversible inhibition of monoamine oxi"}, {"slug": "article-17-neuroinflammation-psilocybin", "url": "https://ootwjournal.com/article-17-neuroinflammation-psilocybin", "title": "The Inflamed Brain: How Psilocybin Resets the Immune-Neural Interface", "description": "Neuroinflammation silently drives depression, cognitive fog, and treatment resistance. Here is the complete science of how psilocybin modulates microglia, cytokines, and the IDO1 pathway to restore mental clarity.", "date": "2026-04-23T08:00:00+00:00", "section": "Neuroscience", "topics": ["neuroscience"], "keywords": [], "excerpt": "Something is quietly on fire inside millions of brains right now. Not metaphorically — literally. The same immune machinery that rushes to a sprained ankle sends sentinel cells into neural tissue, flooding synapses with signalling molecules that reshape thought, mood, and identity. We call this neuroinflammation, and emerging science suggests it may be one of the most underappreciated drivers of modern mental illness. Psilocybin — the compound that has captivated researchers for its rapid, durable antidepressant effects — appears to have a direct and sophisticated relationship with this inflam"}, {"slug": "article-16-vagus-nerve-psilocybin", "url": "https://ootwjournal.com/article-16-vagus-nerve-psilocybin", "title": "The Vagus Nerve: Your Body’s Master Reset Button", "description": "80% of vagal fibres carry signals from gut to brain, not the other way around. Here is the complete science of vagal tone, polyvagal theory, and why it determines how deeply psychedelics can heal.", "date": "2026-04-22T08:00:00+00:00", "section": "Neuroscience", "topics": ["neuroscience"], "keywords": [], "excerpt": "The critical anatomical fact — the one that overturns decades of assumptions — is the 80/20 split of fibre direction. Most people, including many clinicians, conceptualise the vagus nerve as a top-down system: the brain sends calming signals to the body. This is not primarily what the vagus nerve does. It primarily tells the brain what the body is doing. The gut reports its microbiome composition, its inflammatory status, its serotonin production. The heart reports its rate and rhythm. The lungs report their ventilation status. And all of this information flows upward to the nucleus tractus so"}, {"slug": "article-15-oxytocin-psilocybin-social-connection", "url": "https://ootwjournal.com/article-15-oxytocin-psilocybin-social-connection", "title": "Oxytocin, Psilocybin, and the Neuroscience of Social Connection", "description": "How a single molecule transforms how you love, trust, and belong — and what psychedelics reveal about the hidden chemistry of human bonding.", "date": "2026-04-21T00:00:00+00:00", "section": "Neuroscience", "topics": ["neuroscience"], "keywords": [], "excerpt": "There is a molecule in your brain whose entire purpose is to make you feel less alone. It was first identified in 1906, named after the Greek for “swift birth,” and spent most of the twentieth century being studied almost exclusively in the context of childbirth and breastfeeding. Then, in the 1980s and 1990s, neuroscientists began to understand that this molecule — oxytocin — was far more than a uterine contractor. It was the biochemical substrate of belonging. And in the last decade, a convergence of findings has established something remarkable: psilocybin, the compound at the heart of cere"}, {"slug": "article-14-psilocybin-depression-trials", "url": "https://ootwjournal.com/article-14-psilocybin-depression-trials", "title": "Psilocybin and Depression: What Phase 3 Clinical Trials Actually Show", "description": "The most rigorously controlled psychedelic trials in psychiatry history have produced results mainstream medicine hasn’t seen in 40 years. Here’s the complete data — mechanisms, numbers, and what it means for treatment-resistant depression.", "date": "2026-04-20T00:00:00+00:00", "section": "Neuroscience", "topics": ["clinical-research", "veteran-restoration"], "keywords": [], "excerpt": "Psychiatry has had the same tools for 40 years. Selective serotonin reuptake inhibitors — SSRIs — were revolutionary when fluoxetine launched in 1987. Today, they remain the first-line treatment for 280 million people living with depression worldwide. And they fail roughly half of them. For patients who cycle through two or more antidepressant trials without adequate response, psychiatry has a name: treatment-resistant depression (TRD). It affects approximately 100 million people globally. The standard options — dose escalation, augmentation, electroconvulsive therapy — work for some and not o"}, {"slug": "article-13-ego-dissolution", "url": "https://ootwjournal.com/article-13-ego-dissolution", "title": "Ego Dissolution: The Neuroscience of Losing Yourself to Find Yourself", "description": "At high doses, psilocybin doesn't just alter consciousness — it dismantles the neural architecture that constructs the experience of being a separate self. Imperial College London has mapped the mechanism. The Default Mode Network goes quiet. The interior narrator stops. What the research reveals ab", "date": "2026-04-18T08:00:00+00:00", "section": "Neuroscience", "topics": ["neuroscience"], "keywords": [], "excerpt": "There is a moment — documented across hundreds of clinical trial transcripts, across forty years of psychedelic research before prohibition halted it, across ten thousand ceremony reports from Indigenous traditions on every continent — when the sense of being a particular person, in a particular body, with a particular history, simply stops. Not fades. Not blurs. Stops. The interior narrator that normally runs as continuous background commentary goes silent. The boundary between where you end and everything else begins dissolves. What remains is not nothing. What remains is awareness itself, w"}, {"slug": "article-12-theobromine-science", "url": "https://ootwjournal.com/article-12-theobromine-science", "title": "Theobromine: The Heart-Opening Molecule", "description": "The primary alkaloid in ceremonial cacao isn't caffeine. Theobromine — a methylxanthine with a 6–10 hour half-life — dilates blood vessels, crosses the blood-brain barrier, and generates the warm, expansive, heart-forward state that distinguishes ceremonial cacao from every other plant compound on e", "date": "2026-04-17T08:00:00+00:00", "section": "Ceremonial Cacao Science", "topics": ["ceremonial-cacao"], "keywords": [], "excerpt": "Every culture that has used Theobroma cacao — the plant whose name translates literally as \"food of the gods\" — has described the same experience. Warmth spreading from the chest outward. A softening of the protective layer around the heart. An openness to emotion, connection, and presence that arrives without the anxiety or overstimulation of conventional stimulants. Indigenous Maya and Aztec practitioners built entire ceremonial systems around this quality. Modern ceremony facilitators report it consistently. The question that Western pharmacology only recently began asking is: what is the m"}, {"slug": "article-11-psilocin-pharmacokinetics", "url": "https://ootwjournal.com/article-11-psilocin-pharmacokinetics", "title": "From Spore to Synapse: The Journey of Psilocybin Through Your Body", "description": "Psilocybin is pharmacologically inert. The molecule you swallow cannot reach a single receptor in your brain. What happens in the 90 minutes between ingestion and peak experience is a precise biochemical transformation — and understanding it changes everything about how you understand psychedelics.", "date": "2026-04-16T08:00:00+00:00", "section": "Pharmacokinetics", "topics": ["pharmacology"], "keywords": [], "excerpt": "There is a precise moment, roughly twenty to thirty minutes after you swallow a capsule of psilocybin, when something shifts. Not the dramatic transformation you might expect from a psychedelic — more like a subtle brightening at the periphery of perception, a slight loosening of the felt solidity of the world. You might not even be sure it's real yet. But it is real, and it is biochemically exact: the molecule that was psilocybin has become psilocin, crossed from your bloodstream into your brain, and begun to bind 5-HT2A receptors in the deepest layer of your prefrontal cortex. This is not a "}, {"slug": "article-10-serotonin-2a-receptor", "url": "https://ootwjournal.com/article-10-serotonin-2a-receptor", "title": "The 5-HT2A Blueprint: How Psilocybin Speaks to Your Brain", "description": "The single receptor that explains psilocybin's profound transformation of consciousness — its molecular structure, activation cascade, and why blocking it with one drug eliminates the entire psychedelic experience.", "date": "2026-04-15T08:00:00+00:00", "section": "", "topics": ["neuroscience", "pharmacology"], "keywords": [], "excerpt": "In 2018, Katrin Preller at the University of Zurich conducted a decisive experiment. She gave study participants a full dose of LSD — and then administered ketanserin, a drug that selectively blocks a single receptor subtype in the brain. The psychedelic experience disappeared almost completely. Not diminished. Not attenuated. Gone. Colour perception normalized. The dissolution of ego boundaries reversed. The profound sense of interconnectedness, the oceanic boundlessness, the visual complexity — all of it collapsed back into ordinary waking consciousness, while the LSD remained fully active i"}, {"slug": "article-09-set-and-setting-science", "url": "https://ootwjournal.com/article-09-set-and-setting-science", "title": "The Set and Setting Science: How Expectation and Environment Shape the Psilocybin Brain", "description": "Expectation, environment, and intention are not soft variables. They are pharmacologically active — shaping receptor binding, network dynamics, and long-term therapeutic outcomes in ways that clinical data now confirms.", "date": "2026-04-14T08:00:00+00:00", "section": "Psilocybin Neuroscience", "topics": ["integration-science"], "keywords": [], "excerpt": "Same molecule. Same dose. Radically different outcomes. In one session, a participant reports oceanic bliss, lasting psychological integration, and a measurable reduction in depression scores at six-month follow-up. In another, the same milligrams produce terror, paranoia, and weeks of psychological turbulence. The compound — psilocybin — hasn't changed. What changed was the context. The expectation. The environment. The relationship with the guide. This is not a soft observation. It is not anecdotal. It is one of the most replicated findings in the entire literature of psychedelic pharmacolog"}, {"slug": "article-01-your-brain-on-psilocybin", "url": "https://ootwjournal.com/article-01-your-brain-on-psilocybin", "title": "Your Brain on Psilocybin: The Complete Neuroscience of Neural Reconstruction", "description": "How a single compound dissolves rigid neural pathways, triggers structural brain growth, and offers the most promising psychiatric intervention in decades — explained through the science.", "date": "2026-04-08T08:00:00+00:00", "section": "Psilocybin Neuroscience", "topics": ["neuroscience"], "keywords": [], "excerpt": "Something is happening inside clinical neuroscience laboratories that hasn't happened in sixty years. Compounds classified as Schedule I — substances the federal government designated as having \"no accepted medical use\" — are producing treatment outcomes that outperform every pharmaceutical intervention developed since the invention of SSRIs. The compound at the center of this shift is psilocybin. And the science behind it is no longer preliminary. It is structural, measurable, and replicable. This is not a cultural argument. This is not a lifestyle piece. This is a systems-level breakdown of "}, {"slug": "article-02-default-mode-network", "url": "https://ootwjournal.com/article-02-default-mode-network", "title": "The Default Mode Network: Why Your Brain Needs a Hard Reset", "description": "The neural network that constructs your identity is the same one that traps you in depression, anxiety, and PTSD. Understanding it is the first step to dismantling it.", "date": "2026-04-07T08:00:00+00:00", "section": "Psilocybin Neuroscience", "topics": ["neuroscience"], "keywords": [], "excerpt": "You have a narrator inside your skull. It runs continuously. It tells you who you are, what happened to you, what will happen next, and why everything is your fault — or someone else's. It constructs a seamless story out of fragmented perception and calls it \"you.\" Neuroscience has a name for the infrastructure that runs this narrator. It is the Default Mode Network. And for millions of people, it is broken in a way that no conventional treatment has been able to fix. The DMN is not a single brain region. It is a distributed network — a coalition of areas that fire in synchrony when you are no"}, {"slug": "article-03-bdnf-neuroplasticity", "url": "https://ootwjournal.com/article-03-bdnf-neuroplasticity", "title": "BDNF and Neuroplasticity: How Psilocybin Rebuilds Neural Architecture", "description": "Your brain doesn't just think differently after psilocybin. It is physically different. New connections form in 24 hours, persist for months, and rewrite the structural basis of cognition. Here is the protein that makes it happen.", "date": "2026-04-06T08:00:00+00:00", "section": "Psilocybin Neuroscience", "topics": ["neuroscience"], "keywords": [], "excerpt": "The most remarkable claim in psychedelic neuroscience is also the most verifiable. Psilocybin does not merely alter perception. It does not merely shift mood. It causes the physical growth of new neural connections — visible under electron microscopy, measurable in dendritic spine density, persistent for weeks after a single dose. The brain literally rebuilds itself. (See also: psilocybin neuroplasticity and dendritic spines .) And the primary agent of that rebuilding carries a name that sounds like it belongs on a supplement label but represents one of the most important proteins in neuroscie"}, {"slug": "article-04-cacao-psilocybin-synergy", "url": "https://ootwjournal.com/article-04-cacao-psilocybin-synergy", "title": "Ceremonial Cacao × Psilocybin: The Synergy Protocol", "description": "Four bioactive compounds. One ancient pairing. Modern pharmacology now explains why Mesoamerican traditions combined Theobroma cacao with psilocybin — and why the synergy is more than ceremonial.", "date": "2026-04-05T08:00:00+00:00", "section": "Ceremonial Cacao Science", "topics": ["ceremonial-cacao"], "keywords": [], "excerpt": "The Aztecs called cacao \"yollotl eztli\" — the blood of the heart. They called psilocybin mushrooms \"teonanácatl\" — the flesh of the gods. These were not interchangeable sacraments. They were paired. Deliberately. Consistently. Across centuries of ceremonial practice that predated Western pharmacology by a millennium. The tendency in modern psychedelic discourse is to treat this pairing as cultural artifact — anthropologically interesting, pharmacologically irrelevant. That tendency is wrong. The neurochemistry of Theobroma cacao contains at least four compound classes that interact directly wi"}, {"slug": "article-05-veterans-psilocybin-therapy", "url": "https://ootwjournal.com/article-05-veterans-psilocybin-therapy", "title": "From Battlefield to Breakthrough: Psilocybin-Assisted Therapy for Veterans", "description": "22 veterans die by suicide every day. The current standard of care is failing them. Psilocybin-assisted therapy is producing outcomes that redefine what recovery from combat trauma looks like — and it is doing it in sessions, not years.", "date": "2026-04-04T08:00:00+00:00", "section": "Veteran Restoration", "topics": ["clinical-research", "veteran-restoration"], "keywords": [], "excerpt": "There is a number that should be intolerable. Twenty-two. That is the estimated number of U.S. military veterans who die by suicide every single day. Not per month. Not per year. Per day. It is a casualty rate that exceeds every active combat operation the United States is currently engaged in. And it has persisted — at roughly the same level — for over a decade, despite billions of dollars in VA mental health spending. The standard of care is not working. This is not an accusation. It is a measurement. Sertraline, the most commonly prescribed antidepressant for combat-related PTSD, shows resp"}, {"slug": "article-06-microdosing-ceremonial-cacao", "url": "https://ootwjournal.com/article-06-microdosing-ceremonial-cacao", "title": "Microdosing with: Ceremonial Cacao", "description": "Sub-perceptual psilocybin and ceremonial cacao activate complementary neurochemical pathways — producing measurable gains in divergent thinking and social cohesion without the tolerance curves and neurological fatigue that define conventional stimulants.", "date": "2026-04-03T08:00:00+00:00", "section": "Consciousness Protocols", "topics": ["microdosing"], "keywords": [], "excerpt": "The word \"microdose\" has been corrupted by the wellness industry into a synonym for \"feel-good supplement.\" That corruption deserves correction. A microdose is not a mood boost. It is a precise pharmacological intervention operating at the sub-perceptual threshold — a dose calibrated specifically to be below the level that produces any noticeable alteration in perception or consciousness, while still engaging the receptor machinery that mediates the compound's downstream cognitive effects. This distinction matters because it defines what microdosing actually does. You do not feel a microdose t"}, {"slug": "article-07-entropic-brain-hypothesis", "url": "https://ootwjournal.com/article-07-entropic-brain-hypothesis", "title": "The Entropic Brain: Hypothesis", "description": "How increased neural entropy during psychedelic states allows the brain to escape fixed attractor states — the rigid cognitive loops underlying depression, addiction, and chronic psychological suffering — and construct new architectures in their place.", "date": "2026-04-02T08:00:00+00:00", "section": "Consciousness Protocols", "topics": ["neuroscience"], "keywords": [], "excerpt": "In 1944, the physicist Erwin Schrödinger published a small book called What Is Life? In it, he argued that living organisms are distinguished from dead matter by their capacity to import order from their environment — to sustain local decreases in entropy against the thermodynamic current that runs toward disorder. Life, in Schrödinger's framing, is organized resistance to randomness. Seventy years later, Robin Carhart-Harris inverted this logic for the brain — and in doing so produced one of the most consequential frameworks in contemporary neuroscience. His 2014 paper in Frontiers in Human N"}, {"slug": "article-08-psilocybin-addiction", "url": "https://ootwjournal.com/article-08-psilocybin-addiction", "title": "Psilocybin and Addiction: Rewiring the Compulsive Brain", "description": "How a single compound is producing 80% tobacco abstinence rates, 84% reductions in alcohol use, and may represent the most effective addiction intervention ever studied — and the precise neuroscience of why it works.", "date": "2026-04-01T08:00:00+00:00", "section": "", "topics": ["clinical-research"], "keywords": [], "excerpt": "In 2006, Matthew Johnson was a postdoctoral researcher at Johns Hopkins when his mentor Roland Griffiths conducted the first modern double-blind study of psilocybin in healthy volunteers. The results — participants reporting profound mystical experiences, lasting shifts in personality and values, and the highest ratings of personal significance of any event in their lives — were striking enough. But Johnson kept returning to one implication that seemed barely acknowledged in the early papers: if psilocybin could produce this magnitude of psychological reorganization in healthy people, what wou"}]}